KA/EN
Register
Medicines reference
Search
Search
Product

Nobivac DHPPi

Favourites

Canine distemper virus + Canine adenovirus + Canine parvovirus + Canine parainfluenza virus · Intervet International B.V.

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Dog Dog 1 ml
Reconstitute with 1 ml solvent and inject one 1 ml dose subcutaneously. A single dose at 10 weeks or older establishes the core response; if protection is started from 6 weeks, give a final dose at 10 weeks or older. For optimal parainfluenza response, give two doses 2-4 weeks apart, with the final dose at 10 weeks or older. Revaccinate for CDV/CAV/CPV every 3 years and CPi annually. Vaccinate healthy animals only. Wait at least 4 weeks after corresponding antiserum or immunosuppressive drugs. Pregnancy use is limited to previously vaccinated bitches as specified by the SPC. Hypersensitivity, including life-threatening anaphylaxis, is very rare.
 · primary series and revaccination according to the SPC schedule		 primary series and revaccination according to the SPC schedule Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნობივაკ DHPPi
№ 43-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Nobivac DHPPi, Suspension

lyophilisate for suspension for injection, 1 ml dose for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Nobivac DHPPi

lyophilisate for suspension for injection, 1 ml dose for dogs
Assessed clinical scopeDog · Full dog label: active immunisation against CDV, CAV-1/2, CPV and canine parainfluenza, including the labelled primary and component-specific revaccination schedules · Subcutaneous
Care settingPreventive veterinary vaccination with examination, cold-chain control and emergency treatment available
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 43-11 · Verified on 21 Oct 2026

A strong core-plus-parainfluenza vaccine with exact regulatory support and a practical long core interval. The label schedule must still be fitted to maternal-antibody risk and the parainfluenza component does not promise infection-free protection.

Regulatory and scientific credibility9.0/10

The exact one-dose product is registered in Georgia and has a current detailed regulator SPC with transparent strains, potency, schedule, adverse events and component-specific duration claims.

Clinical efficacy8.5/10

CDV, CAV and CPV are strongly supported global core targets and the label supports three-year revaccination; parainfluenza protection is useful but reduces disease and shedding rather than guaranteeing sterile immunity, and maternal antibody may require a later puppy dose.

Safety and tolerability8.4/10

The benefit-risk is favourable in healthy dogs and most reactions are transient; very rare anaphylaxis can be life-threatening, live strains and immunosuppressive treatment need timing safeguards, and pregnancy use is restricted to previously vaccinated bitches.

Clinical practicality8.3/10

The fixed 1 ml SC dose and three-year core interval are practical; reconstitution, immediate use, cold chain, annual parainfluenza decisions and guideline-concordant completion of the puppy series add manageable work.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Vaccinate healthy dogs only; do not use in hypersensitivity to a component.
  • Fit the label course into a guideline-concordant puppy series ending at 16 weeks or later when maternal antibody is relevant.
  • Parainfluenza vaccination reduces clinical signs and shedding but does not guarantee prevention of infection; revaccinate this component annually when risk warrants.
  • Very rare hypersensitivity or anaphylaxis can be life-threatening; observe after vaccination and have immediate treatment available.
  • Wait at least four weeks after corresponding antiserum or immunosuppressive treatment; use other vaccines only as supported by product information.
  • Pregnancy use is limited to previously vaccinated bitches under the exact SPC conditions.
  • Maintain the cold chain, reconstitute aseptically and use the complete 1 ml dose promptly; do not freeze.
Assessment sources
  1. VMD SPC 20252025
  2. WSAVA vaccination 20242024
  3. AAHA canine vaccination 20222022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Canine distemper virus4 log10 TCID50/dose Canine adenovirus4 log10 TCID50/dose Canine parvovirus7 log10 TCID50/dose Canine parainfluenza virus5.5 log10 TCID50/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
Intervet International B.V., Netherlands
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 303, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნობივაკ DHPPi
№ 43-11
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 ml
Reconstitute with 1 ml solvent and inject one 1 ml dose subcutaneously. A single dose at 10 weeks or older establishes the core response; if protection is started from 6 weeks, give a final dose at 10 weeks or older. For optimal parainfluenza response, give two doses 2-4 weeks apart, with the final dose at 10 weeks or older. Revaccinate for CDV/CAV/CPV every 3 years and CPi annually. Vaccinate healthy animals only. Wait at least 4 weeks after corresponding antiserum or immunosuppressive drugs. Pregnancy use is limited to previously vaccinated bitches as specified by the SPC. Hypersensitivity, including life-threatening anaphylaxis, is very rare.
 Dog Any weight Subcutaneous primary series and revaccination according to the SPC schedule
VMD SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Nobivac DHPPi - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Canine distemper virus: No dose supported by a publicly verifiable source yet

Canine adenovirus: No dose supported by a publicly verifiable source yet

Canine parvovirus: No dose supported by a publicly verifiable source yet

Canine parainfluenza virus: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗